Exclusive interview for SPINOFF.COM with Dr. Robert Cucin, CEO of BioSculpture Technology, Inc. on the new generation of liposuction devices that treat obesity and diabetes 

BioSculpture Technology, Inc. (“BST”) is a commercial stage medical device company steeped in the science of adipose tissue. BioSculpture addresses the liposuction and obesity markets with proprietary medical devices and saleable products. In 2013, the Company turned its focus from manufacturing power-assisted devices for the cosmetic liposuction market to developing a minimally invasive device and procedure for the treatment of obesity, metabolic syndrome and Type 2 diabetes mellitus. BST’s mission is to develop and manufacture medical devices and procedures for optimizing fat distribution and metabolism and for tissue aspiration and processing based on medical discoveries and state of the art advances, encompassing the bariatric market, the liposuction and body sculpting market, and the fat and adipocyte-derived stem cell processing and reinjection markets.

BioSculpture Technology 30 second play on load value pitch

SOC: Dear Dr. Cucin, we are so grateful for your generosity this day in spending time speaking with us and sharing your insights about your company, BioSculpture Technology, Inc. and the minimally invasive treatment of Obesity and Type 2 Diabetes it is developing.

Dr. Cucin: You are welcome. I am firmly convinced that the direct approach to the Type 2 Diabetes problem our technology allows is better than current alternatives and welcome every opportunity to explain why I believe should be safer, highly effective, permanent, and cost-saving.

Our investors and we would like to learn more about a vast experience of your academic endeavours and your professional and scientific background.

I graduated magna cum laude in chemistry from  Cornell University and received my M.D. from Weill Cornell Medical College with which I remain affiliated. My Chemistry honours project was on the chemical nature of the lunar surface and supported by NASA.  

I did both my general surgical and plastic surgical residencies at the Presbyterian New York Hospital - Cornell Medical Center and became board-certified in both. I have served as Principal Investigator for both animal (IACUC) and human clinical (IRB) studies there, which I funded through the Rocin Foundation, a not-for-profit research foundation I set up. Of assistance to the business side of running the company is my Columbia MBA.  I am also an attorney admitted to the NY, NJ and DC Bars, I have additional skills which help me navigate IP, licensing and regulatory issues.

Considering your tremendous experience, we would like to know whether you had other projects? Could you please share the story of their creation and success.

Since an early age, I always liked to take things apart, reassemble them, and try making them better. I have always been an inventor and tinkerer and these were not my first patent applications.  

The first patent in this aspiration portfolio was licensed to Mentor by Rocin Laboratories, R&D company I established. The Ethicon Division of J&J acquired both Mentor and the license. It created the power assisted liposuction market, which grew to an estimated $500M/yr. and allowed Mentor to capture roughly 1/4 of it. (Perhaps they would have captured even more of it, but the Arc II Reciprocating Cannula® manufactured and sold by them under my license for $55 required a purchase of their proprietary $9,500 Psi-Tech® aspiration system to utilize. Most surgeons performing liposuction used a cheaper aspiration system which cost approximately half of that, limiting its potential market.)

BioSculpture Technology, Inc. was founded to commercialize the second, more versatile generation of that tissue aspiration technology. These two animations help display the advantage of power assistance with twin cannula construction over single cannula power-assisted liposuction: